FO
|
Grecu
et al
., 2003
d [62]
|
Patients with abdominal sepsis
|
C.Random: Yes
|
PN + Omegaven (10% FO; Fresenius Kabi, Bad Homburg, Germany) plus LCT vs. PN with LCT
|
Omegaven + LCT
|
LCT
|
Omegaven
|
LCT
|
N =54
|
ITT: Yes
|
ICU
|
ICU
|
VAP
|
VAP
|
(15 of 54 in ICU)
|
Blinding: Double
|
2/28 (7)
|
3/26 (12)
|
0/8
|
1/7 (14)
|
(12)
|
Friesecke
et al
., 2008 [63]
|
Medical ICU patients
|
C.Random: Yes
|
PN + Lipofundin (B Braun, Melsungen, Germany) MCT (50% LCT + 50% MCT) + Omegaven (10% FO) vs. PN with Lipofundin MCT (50% LCT + 50% MCT)
|
MCT + LCT + FO
|
LCT + MCT
|
MCT + LCT + FO
|
LCT + MCT
|
N =166
|
ITT: Yes
|
28 days
|
28 days
|
10/83 (12)
|
11/82 (13)
|
Blinding: Double
|
18/83 (22)
|
22/82 (27)
|
(10)
|
Wang
et al
., 2009 [61]
|
Severe acute pancreatitis patients in ICU
|
C.Random: No
|
PN + Omegaven (10% FO) plus Lipovenos (LCT, soybean oil; Fresenius Kabi) (ω3:ω6 ratio was 1:4) vs. PN with Lipovenos (LCT, soybean oil). Both received same amounts of lipids (1 g/kg/day)
|
Omegaven
|
LCT
|
Omegaven
|
LCT
|
N =56
|
ITT: Yes
|
ICU
|
ICU
|
6/28 (21)
|
9/28 (32)
|
Blinding: Double
|
0/28 (0)
|
2/28 (7)
|
(11)
|
Barbosa
et al
., 2010 [64]
|
ICU patients with SIRS or sepsis requiring PN
|
C.Random: Yes
|
PN + Lipolus (50% MCT, 40% LCT soybean oil, 10% FO; B Braun) vs. PN with NuTRIflex Lipid Special (50% MCT, 50% LCT, soybean oil; B Braun). Both received same amounts of lipids (about 1 g/kg/day)
|
MCT + LCT + FO
|
MCT + LCT
|
MCT + LCT + FO
|
MCT + LCT
|
N =25
|
ITT: Yes
|
5 days
|
5 days
|
NR
|
NR
|
Blinding: Single
|
2/13 (15)
|
1/10 (10)
|
(10)
|
28 days
|
28 days
|
4/13 (31)
|
4/10 (40)
|
Gupta
et al
., 2011 [15]
|
ICU patients with suspected ARDS
|
C.Random: Yes
|
EN (standard diet) + Omegaven 10% (ω3:ω6 ratio was 1:4) vs. EN (standard diet)
|
Omegaven
|
Standard
|
NR
|
NR
|
N =61
|
ITT: Yes
|
ICU
|
EN
|
Blinding: Double
|
7/31 (23)
|
ICU
|
(9)
|
Hospital
|
13/30 (43)
|
9/31 (29)
|
Hospital
|
14/30 (47)
|
Khor
et al
., 2011 [16]
|
ICU patients with severe sepsis/septic shock
|
C.Random: Yes
|
Supplementation with 100 ml of 10% Omegaven (10 g of refined FO, EPA 12.5 to 28.2 g/L, DHA 14.4 to 30.9 g/L) vs. 100 ml of 0.9% normal saline
|
NR
|
NR
|
NR
|
NR
|
N =28
|
ITT: No
|
Blinding: Double
|
(8)
|
Burkhart
et al
., 2013 [18]
|
ICU patients with sepsis
|
C.Random: ?
|
2 ml/kg/day Omegaven vs. no parenteral FO. Both groups received EN and/or PN without added FO at the discretion of the clinician.
|
Omegaven
|
No Omegaven
|
NR
|
NR
|
N =50
|
ITT: Yes
|
Hospital
|
Hospital
|
Blinding: Single (assessor)
|
13/25 (52)
|
13/25 (52)
|
(8)
|
Grau-Carmona
et al
., 2014 [65]
|
Medical and surgical patients requiring PN
|
C.Random: Yes
|
PN + Lipoplus (50% MCT, 40% LCT soybean oil, 10% FO; B Braun) vs. PN + Lipofundin (50% LCT + 50% MCT)
|
MCT + LCT + FO
|
MCT + LCT ICU
|
MCT + LCT + FO
|
MCT + LCT
|
N =175
|
ITT: Yes
|
ICU
|
16/78 (20.5)
|
17/81 (21)
|
29/78 (37.2)
|
Blinding: Double
|
26/81 (32.5)
|
Hospital
|
(10)
|
Hospital
|
6/78 (9.7)
|
6/81 (11.1)
|
6 months
|
6 months
|
2/78 (3.6)
|
2/81 (4.3)
|
Gultekin
et al
., 2014 [66]
|
ICU patients needing TPN
|
C.Random: ?
|
PN + Omegaven (10% FO) plus ClinOleic (80% olive oil, 20% soybean oil; Baxter Healthcare, Compton, UK) vs. PN + ClinOleic
|
Omegaven + olive oil
|
Olive oil
|
NR
|
NR
|
N =58
|
ITT: Other
|
Unspecified
|
Unspecified
|
Blinding: Double
|
8/16 (50)
|
7/16 (44)
|
(3)
|
Hall
et al
., 2014 [17]
|
ICU patients with sepsis
|
C.Random: ?
|
Omegaven dosed at 0.2 g of FO/kg/day given at a rate of 0.05 g of FO/kg/day vs. no FO. Both groups received EN and/or PN at the discretion of the clinician.
|
Omegaven
|
No Omegaven
|
Omegaven
|
No Omegaven
|
N =60
|
ITT: Yes
|
Hospital
|
Hospital
|
3/30 (10)
|
5/30 (16.7)
|
Blinding: No
|
4/30 (13.3)
|
9/30 (30)
|
(9)
|
28 days
|
28 days
|
4/30 (13.3)
|
8/30 (26.7)
|